Cognitive function and breast cancer molecular subtype before and after chemotherapy.
Saved in:
| Title: | Cognitive function and breast cancer molecular subtype before and after chemotherapy. |
|---|---|
| Authors: | Hsu, Yen-Hsuan (AUTHOR), Chen, Hui-Jyuan (AUTHOR), Wu, Shu-I (AUTHOR), Tzang, Bor-Show (AUTHOR), Hsieh, Ching-Chuan (AUTHOR), Weng, Yi-Ping (AUTHOR), Hsu, Ya-Ting (AUTHOR), Hsiao, Han-Pin (AUTHOR), Chen, Vincent Chin-Hung (AUTHOR) |
| Source: | Applied Neuropsychology: Adult. Mar/Apr2025, Vol. 32 Issue 2, p442-449. 8p. |
| Subjects: | Epidermal growth factor receptors, Executive function, Cognitive processing speed, Cognitive testing, Verbal memory |
| Abstract: | Chemotherapy-related cognitive impairment has been reported in patients with breast cancer and received growing attention due to increased survival rate. However, cognitive outcome according to pathological tumor features, especially human epidermal growth factor receptor (HER2) status, has not been clearly elucidated. Despite its potential link with cognitive status through neuroinflammatory response, existing research is sparse and limited to cross-sectional studies. In this observational cohort study, 52 breast cancer patients received a series of neuropsychological examinations before and after chemotherapy. Patients' performances were compared with normative data, and analyzed with Reliable Change Indices and mixed-model analysis of covariance. Results showed that there was a higher percentage of HER2+ patients than HER2− patients who showed defective attention and processing speed before chemotherapy, and that there were more patients with HER2+ status showing cognitive decline on tests of attention and executive functions following chemotherapy. Group-wise analyses confirmed the foregoing pattern and further revealed that patients with HER2+ status also tended to deteriorate more in verbal memory after chemotherapy. These findings indicate that HER2 overexpression may serve as prognostic factors that help explain the heterogeneous cognitive outcome in breast cancer survivors. Further studies are needed to replicate this finding and delineate the underlying mechanisms. [ABSTRACT FROM AUTHOR] |
| Copyright of Applied Neuropsychology: Adult is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Chemotherapy-related cognitive impairment has been reported in patients with breast cancer and received growing attention due to increased survival rate. However, cognitive outcome according to pathological tumor features, especially human epidermal growth factor receptor (HER2) status, has not been clearly elucidated. Despite its potential link with cognitive status through neuroinflammatory response, existing research is sparse and limited to cross-sectional studies. In this observational cohort study, 52 breast cancer patients received a series of neuropsychological examinations before and after chemotherapy. Patients' performances were compared with normative data, and analyzed with Reliable Change Indices and mixed-model analysis of covariance. Results showed that there was a higher percentage of HER2+ patients than HER2− patients who showed defective attention and processing speed before chemotherapy, and that there were more patients with HER2+ status showing cognitive decline on tests of attention and executive functions following chemotherapy. Group-wise analyses confirmed the foregoing pattern and further revealed that patients with HER2+ status also tended to deteriorate more in verbal memory after chemotherapy. These findings indicate that HER2 overexpression may serve as prognostic factors that help explain the heterogeneous cognitive outcome in breast cancer survivors. Further studies are needed to replicate this finding and delineate the underlying mechanisms. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 23279095 |
| DOI: | 10.1080/23279095.2023.2176233 |
